Asthma and Respiratory Disorders News

Researchers used machine learning to identify 25 combinations of air pollutants that were associated with increased asthma symptoms among children in Spokane, Washington, according to a study published in Science of the Total Environment.

The U.S. Environmental Protection Agency has finalized stricter limits on emissions from model year 2027 through 2032 passenger cars, light-duty trucks and medium-duty vehicles, according to a press release from the agency.

WASHINGTON — In a population of 1,000 adolescents with asthma, most had smartphone and internet access, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Vanessa Murphy, PhD, started her research career in a lab studying preterm birth, which is where she fell in love with pregnancy research.

WASHINGTON — Rebamipide has potential as treatment for low-grade inflammation among patients with post-COVID syndrome, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Compared with white, Asian and Hispanic children, African American children more frequently visited the ED because of asthma or a food allergy, according to study findings.

Children with severe allergic asthma and serum total IgE levels between 1,500 kU/L and 3,300 kU/L as well as food allergy benefitted from omalizumab, according to a study published in Pediatric Allergy and Immunology.

A medium inhaled corticosteroid dose plus a long-acting beta agonist was found to be the most beneficial step-up treatment option for children with uncontrolled asthma, according to a meta-analysis published in European Respiratory Journal.

WASHINGTON — Concentrations of indoor pest allergens were consistently associated with upper respiratory infections, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Allergic status did not impact annualized asthma exacerbation rate reductions seen with mepolizumab, benralizumab and tezepelumab in patients with moderate to severe, uncontrolled asthma, according to study results.